OraSure to Present at J.P Morgan Healthcare Conference

Pulmocide recently completed a Phase 2 safety and tolerability clinical trial (OPERA-S study) in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary ...
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced ...
Then, next week, Nvidia is on the road again at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, which ...
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
Commenting on being selected to speak at the conference, Dr. Sinkule stated: “I am delighted to have the honor of presenting at this prestigious conference. I welcome the opportunity of sharing ...